Interní Med. 2017; 19(1): 29-32 | DOI: 10.36290/int.2017.004

Dual inhibition in the treatment of heart failure

doc. MUDr. Filip Málek, Ph.D., MBA
Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

Dual inhibition in the therapy of heart failure consist of drugs blocking renin-angiotensin-aldosteron system and inhibiting neutral

endopeptidase – neprilysin – responsible for endogenous natriuretic peptides degradation. Sacubitril/valsartan is neprilysin

inhibitor and angiotensin receptor blocker and is the only representant of new drug group among other drugs modifying natural

history of heart failure.

Keywords: heart failure, pharmacotherapy, angiotensin receptor blocker, neutral endopeptidase inhibitor, sacubitril/valsartan

Published: February 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Dual inhibition in the treatment of heart failure. Interní Med. 2017;19(1):29-32. doi: 10.36290/int.2017.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. CIBIS Investigators and Commities. The Cardiac Insufficiency Bisoprolol Study II. (CIBIS II). Lancet, 1999; 353: 9-13. Go to original source...
    2. MERIT-HF Study Group. Effect of Metoprolol CR/XL in Chronic Heart Failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure. Lancet 1999; 353: 2001-2007. Go to original source...
    3. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658. Go to original source... Go to PubMed...
    4. Flather MD, Shibata MC, Coats AJ, et al., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225. Go to original source... Go to PubMed...
    5. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure.Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-1435.
    6. Rogers WJ, Johnstone DE,Yusuf S, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302. Go to original source... Go to PubMed...
    7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 753-755. Go to original source... Go to PubMed...
    8. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21. Go to original source... Go to PubMed...
    9. Wilkins MR, Redondo J. The natriuretic peptide-family. Lancet 1997; 349: 1307-1310. Go to original source... Go to PubMed...
    10. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompesated heart failure. N Engl J Med 2011; 365: 32-43. Go to original source... Go to PubMed...
    11. Margulies KB, Barclay PL, Burnett JC Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995; 91: 2036-2042. Go to original source... Go to PubMed...
    12. Packer M, Califf RM, Konstam MA, et al. for the OVERTURE Study Group Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure Circulation 2002; 106: r21-r27. Go to original source... Go to PubMed...
    13. McMurray JJ, Packer M, Desai AS, et al. Angiotensin neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004. Go to original source... Go to PubMed...
    14. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Heart Journal doi:10.1093/eurheartj/ehw128. Go to original source... Go to PubMed...
    15. Bonow R. New Insights Into the Cardiac Natriuretic Peptides. Circulation 1996; 93(11): 1946-1950. Go to original source... Go to PubMed...
    16. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1996; 94: 3184-3189. Go to original source... Go to PubMed...
    17. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. New Engl J Med 2000; 343: 264-253. Go to original source... Go to PubMed...
    18. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-620. Go to original source... Go to PubMed...
    19. Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan Heart 2016; 0: 1-6.
    20. SPC Entresto http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf
    21. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF) https://clinicaltrials.gov/ct2/show/NCT01920711.
    22. Packer M, McMurray JJ, Desai AS, et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure Circulation 2015; 131: 1-8. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.